Table 2.
Numbers and rates of CVD events and MACE both overall and separately by preceding microvascular event status
| Any CVD, n (rate*) | MACE, n (rate*) | |
|---|---|---|
| Overall | 239 (6.1) | 120 (3.0) |
| Microvascular outcome | ||
| PDR (n = 360) | ||
| Yes | 69 (14.1) | 39 (7.4) |
| No | 170 (5.0) | 81 (2.3) |
| CSME (n = 413) | ||
| Yes | 76 (13.0) | 45 (7.2) |
| No | 163 (4.9) | 75 (2.2) |
| Three-step progression (n = 972) | ||
| Yes | 150 (8.2) | 82 (4.3) |
| No | 89 (4.3) | 38 (1.8) |
| PDR and/or CSME (n = 525) | ||
| Yes | 99 (12.8) | 58 (7.0) |
| No | 140 (4.4) | 62 (1.9) |
| AER ≥300 (n = 172) | ||
| Yes | 39 (16.1) | 27 (10.3) |
| No | 200 (5.4) | 93 (2.5) |
| Sustained AER ≥30 (n = 457) | ||
| Yes | 103 (12.4) | 57 (6.4) |
| No | 136 (4.4) | 63 (2.0) |
| eGFR <60 (n = 147) | ||
| Yes | 31 (28.4) | 20 (15.9) |
| No | 208 (5.5) | 100 (2.6) |
| Sustained AER ≥30 mg/24 h and/or eGFR <60 mL/min/1.73 m2 (n = 498) | ||
| Yes | 110 (12.8) | 60 (6.5) |
| No | 129 (4.2) | 60 (1.9) |
| CAN (n = 589) | ||
| Yes | 99 (12.1) | 57 (6.5) |
| No | 140 (4.5) | 63 (2.0) |
| Presence of retinal and kidney disease+ | ||
| 0 | 94 (3.5) | 41 (1.5) |
| 1 | 81 (9.1) | 40 (4.3) |
| 2 | 64 (17.1) | 39 (9.6) |
*
Per 1,000 patient-years. +Presence of retinal and kidney disease is a quantitative variable defined as 0, no prior complications; 1, prior (PDR and/or CSME) or (severe albuminuria (AER ≥300 mg/24 h) and/or sustained eGFR <60 mL/min/1.73 m2) but not both; and 2, prior (PDR and/or CSME) and (severe albuminuria (AER ≥300 mg/24 h) and/or sustained eGFR <60 mL/min/1.73 m2).